Annual Shareholders Equity
$246.11 M
-$43.12 M-14.91%
December 31, 2023
Summary
- As of February 7, 2025, CCCC annual stockholders equity is $246.11 million, with the most recent change of -$43.12 million (-14.91%) on December 31, 2023.
- During the last 3 years, CCCC annual shareholders equity has fallen by -$34.68 million (-12.35%).
- CCCC annual shareholders equity is now -36.83% below its all-time high of $389.61 million, reached on December 31, 2021.
Performance
CCCC Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Shareholders Equity
$242.66 M
-$4.40 M-1.78%
September 30, 2024
Summary
- As of February 7, 2025, CCCC quarterly stockholders equity is $242.66 million, with the most recent change of -$4.40 million (-1.78%) on September 30, 2024.
- Over the past year, CCCC quarterly shareholders equity has increased by +$26.63 million (+12.33%).
- CCCC quarterly shareholders equity is now -41.73% below its all-time high of $416.43 million, reached on June 30, 2021.
Performance
CCCC Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Shareholders Equity Formula
Shareholders Equity = Total Assets − Total Liabilities
CCCC Shareholders Equity Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -14.9% | +12.3% |
| 3 y3 years | -12.3% | +12.3% |
| 5 y5 years | +408.6% | +12.3% |
CCCC Shareholders Equity Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -36.8% | at low | -37.7% | +12.3% |
| 5 y | 5-year | -36.8% | +319.8% | -41.7% | +255.6% |
| alltime | all time | -36.8% | +319.8% | -41.7% | +255.6% |
C4 Therapeutics Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $242.66 M(-1.8%) |
| Jun 2024 | - | $247.06 M(-4.3%) |
| Mar 2024 | - | $258.28 M(+4.9%) |
| Dec 2023 | $246.11 M(-14.9%) | $246.11 M(+13.9%) |
| Sep 2023 | - | $216.02 M(-7.6%) |
| Jun 2023 | - | $233.71 M(-11.0%) |
| Mar 2023 | - | $262.47 M(-9.3%) |
| Dec 2022 | $289.23 M | $289.23 M(-9.1%) |
| Sep 2022 | - | $318.18 M(-7.7%) |
| Jun 2022 | - | $344.59 M(-5.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $364.53 M(-6.4%) |
| Dec 2021 | $389.61 M(+38.8%) | $389.61 M(-2.3%) |
| Sep 2021 | - | $398.78 M(-4.2%) |
| Jun 2021 | - | $416.43 M(+57.9%) |
| Mar 2021 | - | $263.70 M(-6.1%) |
| Dec 2020 | $280.79 M(-350.8%) | $280.79 M(-280.1%) |
| Sep 2020 | - | -$155.92 M(-226.0%) |
| Jun 2020 | - | $123.78 M(-210.6%) |
| Dec 2019 | -$111.96 M(+40.4%) | -$111.96 M |
| Dec 2018 | -$79.75 M | - |
FAQ
- What is C4 Therapeutics annual stockholders equity?
- What is the all time high annual shareholders equity for C4 Therapeutics?
- What is C4 Therapeutics annual shareholders equity year-on-year change?
- What is C4 Therapeutics quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for C4 Therapeutics?
- What is C4 Therapeutics quarterly shareholders equity year-on-year change?
What is C4 Therapeutics annual stockholders equity?
The current annual shareholders equity of CCCC is $246.11 M
What is the all time high annual shareholders equity for C4 Therapeutics?
C4 Therapeutics all-time high annual stockholders equity is $389.61 M
What is C4 Therapeutics annual shareholders equity year-on-year change?
Over the past year, CCCC annual stockholders equity has changed by -$43.12 M (-14.91%)
What is C4 Therapeutics quarterly stockholders equity?
The current quarterly shareholders equity of CCCC is $242.66 M
What is the all time high quarterly shareholders equity for C4 Therapeutics?
C4 Therapeutics all-time high quarterly stockholders equity is $416.43 M
What is C4 Therapeutics quarterly shareholders equity year-on-year change?
Over the past year, CCCC quarterly stockholders equity has changed by +$26.63 M (+12.33%)